Navigation Links
Weikang Bio-Technology Reports Second Quarter 2010 Financial Results
Date:8/16/2010

and operating margin was 35.8%.

Net income was $1.9 million in the second quarter of 2010, down 42.5% from $3.3 million in net income from the same period a year ago. Fully diluted earnings per share were $0.07 compared to fully diluted earnings per share of $0.13 in the second quarter of 2009. Excluding the non-cash, stock-based compensation, non-GAAP net income and fully diluted earnings per share for the second quarter of 2010 was $2.8 million and $0.10, respectively.

Financial Condition

As of June 30, 2010, Weikang Bio-Technology Group Co., Inc. had $20.5 million in cash and cash equivalents, $20.3 million in working capital and $13.4 million in total liabilities. Net cash provided by operating activities for the first six months of 2010 was $7.2 million. Shareholders' equity stood at $34.2 million, up from $23.4 million at year end 2009.

Six Months Financial Results

Revenue for the first six months of fiscal 2010 was $24.5 million, up 5% from $23.3 million in the same period a year ago. Gross profit was $14.4 million, up 13.3% from gross profit of $12.7 million for the first six months of fiscal 2009. Gross margin was 59.0% compared to 54.7% for the comparable period a year ago. Operating income was $9.2 million, up slightly from $9.1 million in the first six months of fiscal 2009. Adjusting for $1.9 million in non-cash, stock-based compensation, non-GAAP operating income was $11.1 million. Net income was $6.5 million, down 10.0% from $7.2 million in the same period a year ago. Fully diluted earnings per share were $0.23 compared to $0.28 in the first six months of fiscal 2009. Excluding the non-cash, stock-based compensation, non-GAAP net income and fully diluted earnings per share for the first six months of 2010 was $8.3 million and $0.30.

Recent Events

Mr. Baolin Sun was appointed as
'/>"/>

SOURCE Weikang Bio-Technology Group Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
2. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
3. Par Pharmaceutical Reports Second Quarter 2008 Results
4. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
5. Pharmos Corporation Reports 2008 Second Quarter Results
6. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
7. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
8. BMP Sunstone Reports Second Quarter 2008 Financial Results
9. ULURU Inc. Reports Second Quarter 2008 Financial Results
10. Immtech Reports Fiscal First Quarter 2009 Results
11. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - Resverlogix ... of common shares of Resverlogix have approved the ... Eastern Capital Limited of 5,600,000 units at a ... Placement"), each unit being comprised of one common ... aggregate proceeds of approximately CAD$15 million; and (ii) ...
(Date:6/30/2015)... , June 30, 2015  Today, Americord Registry, one ... announced Andrew Horne , a partner at Kirkland & ... Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   ... Americord,s Advisory Board," says Martin Smithmyer , CEO of ... his legal career that will assist Americord,s growth and vision." ...
(Date:6/30/2015)... ... 2015 , ... The maximum number of shares proposed to be purchased in ... of unvested restricted stock). On June 29, 2015, the last trading day prior to ... on the OTCBB was $2.29 per share. , The tender offer will expire on ...
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - RepliCel Life ... stage regenerative medicine company focused on the development ... participant in its Phase 1/2 clinical trial of ... unilateral Achilles tendinosis, has been enrolled and their ... ultrasound-guided injections. RCT-01 is comprised of non-bulbar dermal ...
Breaking Biology Technology:Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3Americord Registry Announces Andrew Horne as Advisory Board Member 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4
... Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) today ... 2007 financial results after the NASDAQ Global Market ... Jack Lief, Arena,s,President and Chief Executive Officer, and ... Financial Officer, will host a conference call,at 5:00 ...
... Phase 3 Trials for Crohn,s Disease, Pouchitis and ... ... Ocera Therapeutics, a,biopharmaceutical company focused on the licensing, development and,commercialization ... liver diseases, has announced the completion of a,$35.5 million Series ...
... Osteotech, Inc.,(Nasdaq: OSTE ), a leader in ... today that total revenue for the year,ending December 31, ... for the year ended December 31, 2006. Revenue from ... for full year,2007, an increase of 15% over core ...
Cached Biology Technology:Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008 2Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008 3Ocera Therapeutics Closes $35.5 Million Series C Financing 2Ocera Therapeutics Closes $35.5 Million Series C Financing 3Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 2Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 3Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 4Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 5Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 6
(Date:6/9/2015)... 2015 Research and Markets  ( http://www.researchandmarkets.com/research/xsgs2s/gesture ... "Gesture Recognition & Touchless Sensing Market by Technology ... Others), Product (Biometric & Sanitary Equipment) & by ... to their offering. The total gesture ... reach $ 23.55 Billion by 2020 at a ...
(Date:6/8/2015)... , June 8, 2015  The Secure ... their selection of Troy Potter of ... immediately. SIBA is a non-profit association that was ... policy, education and implementation of solutions that protect ... ...
(Date:6/4/2015)... the co-chairs of the Blue Ribbon Study Panel on Biodefense ... USA Today,s investigative report ... findings of lax safety standards and called on the federal ... "The state of oversight of ... Lieberman , former senator and co-chair of the Blue Ribbon ...
Breaking Biology News(10 mins):Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 3Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 4Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 5Biodefense Panel Expresses Grave Concerns over Findings at Nation's Research Labs 2Biodefense Panel Expresses Grave Concerns over Findings at Nation's Research Labs 3
... September 8, 2008For allergy sufferers, the choice all too ... curtains or anything that could trigger indoor allergens. ... with the launch of Clorox® Anywhere® Anti-Allergen Fabric Spray, ... fabric surfaces in the home. Clorox® Anywhere® ...
... Francis S. Collins, M.D., Ph.D., a physician-geneticist and ... with the new Inamori Ethics Prize from the Inamori ... Reserve University. Modeled after the Nobel and Kyoto ... Inamori Ethics Prize instead honors outstanding international ethical leaders. ...
... headed by Prof. Daniel Rosenfeld of the Institute of ... come up with a surprising finding to the disputed ... The conclusion: both can be true, depending on local ... is one with significant consequences in an era of ...
Cached Biology News:The Clorox Company's new indoor allergen product reduces common indoor allergens up to 90 percent 2Leader of Human Genome Project honored with the Inamori Ethics Prize 2Dirty air brings rain -- then again, maybe not 2Dirty air brings rain -- then again, maybe not 3
... Acid Resistant SpeedVac Model SPD131DDA , ... The SPD131DDA is designed to handle the rigors ... new slim design, digital display, dual independent timers, ... coated chamber and vapor pathway. , , ...
...
For absolute protein quantification. 4 peptides in 5 vials x 2 nmol per peptide...
The PxE Thermal Cycler (PxE) is a licensed 96 well PCR machine, developed to provide all fundamental features for value for money thermal cycling....
Biology Products: